Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Haemonetics Corporation

Stage 2 · Advancing · week 17

As of Oct 22, 2026, Haemonetics is in Stage 2, the uptrend phase, now in week 17 (since Jun 24, 2026). It closed at $116.16, 4.8% below its 52-week high and above its 200-day average, which is rising.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. More about the company

$116.16
-0.81% today
$5.3B · Mid cap
Market Neutral — Fading

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is HAE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S4 16w
S2 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 9w → S3 9w → S4 16w → S1 4w → S2 9w → S3 6w → S4 11w → S1 11w → S4 16w → S1 9w → S2 3w → S4 13w → S1 4w → S2 9w → S3 5w → S4 11w → S1 3w → S2 17w current
Total tracked: 166 weeks across 18 stage runs.

HAE among Medical Devices4th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
vs 52W High
-4.8%
$49.44 lo$122.06 hi
4.8% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 17
1w13w26w
Week 17, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
49.9%
200 DMA: $77.49 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.51x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+8.7%
3M
+47.4%
6M
+94.8%
YTD
+45.2%
1Y
+126.9%
Scan Membership
Breakout Watch
Latest: 2024-05-14
6 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 17 · Vol 0.51x
2026-10-21S2
Wk 17 · Vol 1.17x
2026-10-20S2
Wk 17 · Vol 0.82x
2026-10-19S2
Wk 17 · Vol 0.55x
2026-10-16S2
Wk 17 · Vol 0.64x
2026-10-15S2
Wk 16 · Vol 1.01x
2026-10-14S2
Wk 16 · Vol 0.78x
2026-10-13S2
Wk 16 · Vol 1.09x
2026-10-12S2
Wk 16 · Vol 1.18x
2026-10-09S2
Wk 16 · Vol 1.68x
2026-10-08S2
Wk 15 · Vol 3.93x
2026-10-07S2
Wk 15 · Vol 0.88x
Moving averages & range
50 DMA
$107.52
200 DMA
$77.49
52W High
$122.06
52W Low
$49.44
5D Low
$116.16
Resistance levels (recent highs)
20d High
$122.06
60d High
$122.06
120d High
$122.06
250d High
$122.06
Next resistance
+5.1%
to 20d High
P/E (TTM)
56.1
Forward 20.1
Earnings Growth (YoY)
+2.9%
Revenue +5.6%
ROE
+11.2%
Profit margin +7.1%
Dividend Yield
0.00%
P/B 6.3

Haemonetics: quick answers

What stage is Haemonetics in?

As of Oct 22, 2026, Haemonetics (HAE) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 24, 2026 and is in week 17. What the four stages mean

Is Haemonetics in an uptrend?

Yes. Haemonetics is in a Stage 2 uptrend. It trades 49.9% above its 200-day average, which is rising.

How far is Haemonetics from its 52-week high?

Haemonetics closed at $116.16 on Oct 22, 2026, 4.8% below its 52-week high of $122.06. Its 52-week low is $49.44.

How has Haemonetics performed over the past year?

As of Oct 22, 2026, Haemonetics is up 126.9% over the past year and up 45.2% so far in 2026.

Which sector and industry is Haemonetics in?

Haemonetics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.